D Wave Quantum Inc (QBTS): IONQ vs QBTS

Monksdream · 2024-12-17T19:26:15.3200000Z

IONQ vs QBTS https://investorshub.advfn.com/uimage/uploads/2024/12/17/nuchbIMG_4003.gif

Play Episode

7min

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

COSOL Sees U.S. market as key growth driver

COSOL Limited Managing Director Scott McGowan talked with Proactive at AIM's Small and Midcap Conference about the company’s role in driving operational efficiency across asset-intensive industries. COSOL Limited works with organisations in mining, oil and gas, utilities, and public infrastructure to enhance the performance of their physical assets. McGowan explained the company’s core service as unlocking value by helping clients reduce costs through better asset management. “We look at ways that we can save them real dollars to be able to manage that asset more effectively,” he said. The company’s client list includes major names such as Glencore, Rio Tinto, BHP, and several government departments. COSOL provides the systems and processes behind the scenes to manage these organisations’ equipment and facilities, potentially impacting hundreds of millions in operational costs. Even a 2–3% improvement, McGowan said, “makes a significant difference to their bottom line.” COSOL has grown revenue from AUD 30 million to over AUD 110 million since listing. It is now targeting organic growth in the mid-teens and exploring earnings-accretive acquisitions. McGowan also highlighted COSOL’s presence in the U.S., describing it as the company’s largest potential market, where current operations may be expanded through acquisition. #COSOL #ASXStocks #ScottMcGowan #AssetManagement #MiningTech #Utilities #PublicInfrastructure #OperationalEfficiency #DataSolutions #IndustrialSoftware #GrowthStocks #USExpansion #InvestingInTech -

Proactive - Interviews for investors

AI translation tech: Straker CEO talks IBM partnership

Straker Ltd CEO Grant Straker talked with Proactive at AIM"S Small and Midcap Conference about how the company is leveraging artificial intelligence to reshape the global language services industry. Straker explained how the business evolved from early content management systems into a leading AI-powered translation platform over the last 15 years. The company focuses on blending machine learning with human expertise to deliver high-quality, cost-effective language services. A key milestone has been the integration of its platform by IBM, which now uses Straker’s technology for all its internal translations. “They’ve gone from a multi-vendor traditional model to just us,” Straker said, highlighting how the move has streamlined IBM’s operations while reducing costs. He also discussed the company's proprietary "Terry" language model and its innovative quality estimation* system. This tool evaluates translated content for accuracy, determining whether it needs human review—improving efficiency and boosting gross margins. Straker outlined a clear investor case, emphasizing three pillars: financial strength, innovation, and global distribution. The company is targeting revenues of AUD 45 million for the year, with no debt, AUD 12 million in cash, and annual R&D investment of AUD 7 million. With operations in ten countries and strategic alignment with IBM’s AI stack, Straker positioned the company as well-placed to scale quickly through operating leverage in AI. #AI #StrakerLtd #GrantStraker #LanguageTech #TranslationAI #IBMPartnership #ArtificialIntelligence #InvestorUpdate #MachineTranslation #TechStocks #ASXStocks #TerryModel #QualityEstimation #ProactiveInvestors #SmallCapASX

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Followers	290
Posts	59763
Boards Moderated	3
Alias Born	08/29/2007

Volume:	14,756,708
Day Range:	6.75 - 7.14
Bid:
Ask:
Last Trade Time:	11:12:03 AM EDT
Total Trades:	48,073

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

QBTS Detailed Quote

Recent QBTS News

More QBTS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent QBTS News

Go Ad-Free